Business Wire

Business Wire is the global leader in news release distribution and regulatory disclosure. Business Wire delivers news and multimedia directly into editorial systems and leading online news platforms and is a trusted source for news organisations, journalists, investment professionals and regulatory authorities.

Results: 2725-2736 of 20566

Liberty Latin America Expands Exclusive International Voice Managed Services Partnership with BTS to 22 Additional Caribbean Markets

Det-Tronics Acquires Optronics

Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease

Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base

GEOLOG Acquires Quad Ltd and QO Inc. to Enhance Global Wellsite Geology and Pore Pressure Services

FGS Global launches 2026 Radar Report: "A Rewired World"

Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO

AF Blakemore Selects Logile to Standardise Labour Planning Across Its Retail Estate

Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony.

FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics